FDA Flags Liver Injury Risk In Sanofi's Rejected Multiple Sclerosis Drug

Benzinga_recent_news01-06

In December 2025, the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) for Sanofi SA's (NASDAQ:SNY) new drug application of tolebrutinib to treat non-relapsing secondary...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601186358?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/06/Gentilly--France--March-21--2021-Sign-An.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-01-06 21:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601186358","market":"sh","top_or_hot":-1,"title":"FDA Flags Liver Injury Risk In Sanofi's Rejected Multiple Sclerosis Drug","media":"Benzinga_recent_news","content":"<div>\n<p>In December 2025, the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) for Sanofi SA's (NASDAQ:SNY) new drug application of tolebrutinib to treat non-relapsing secondary...</p>\n\n<a href=\"https://www.benzinga.com/news/fda/26/01/49721626/fda-flags-liver-injury-risk-in-sanofis-rejected-multiple-sclerosis-drug\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Flags Liver Injury Risk In Sanofi's Rejected Multiple Sclerosis Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Flags Liver Injury Risk In Sanofi's Rejected Multiple Sclerosis Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-06 21:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/fda/26/01/49721626/fda-flags-liver-injury-risk-in-sanofis-rejected-multiple-sclerosis-drug><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In December 2025, the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) for Sanofi SA's (NASDAQ:SNY) new drug application of tolebrutinib to treat non-relapsing secondary...</p>\n\n<a href=\"https://www.benzinga.com/news/fda/26/01/49721626/fda-flags-liver-injury-risk-in-sanofis-rejected-multiple-sclerosis-drug\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.benzinga.com/news/fda/26/01/49721626/fda-flags-liver-injury-risk-in-sanofis-rejected-multiple-sclerosis-drug","article_id":"2601186358","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/06/Gentilly--France--March-21--2021-Sign-An.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/26/01/49721626/fda-flags-liver-injury-risk-in-sanofis-rejected-multiple-sclerosis-drug","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2601186358","pubTimestamp":1767707640,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"The FDA rejected Sanofi's MS drug tolebrutinib, citing liver injury risks, unclear benefits, and trial data that failed to show a favorable benefit-risk balance for any patient group.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","CRL":"查尔斯河","BK4585":"ETF&股票定投概念","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","SNYNF":"Sanofi","IE00BFMHRM44.USD":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","BK4121":"生命科学工具和服务","BK4530":"医药外包概念","SNY":"赛诺菲安万特","BK4007":"制药"},"translate_title":"FDA标记赛诺菲被拒绝的多发性硬化症药物存在肝损伤风险","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRL":1,"SNY":1,"SNYNF":1.5},"content_text":"In December 2025, the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) for Sanofi SA's (NASDAQ:SNY) new drug application of tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis (nrSPMS) in adult patients.\nThe press release was thin on information related to the rejection. The FDA publicly shared the complete response letter, citing both efficacy and safety concerns.\nThe regulatory agency wrote that, \"a favorable benefit-risk profile could not be established for any patient subpopulation.\"\nAlso Read: Sanofi Expands Dren Bio Partnership With Potential $1.7 Billion Autoimmune Disease Collaboration\nThe FDA determined a serious risk of severe drug-induced liver injury (DILI) identified during clinical trials and noted that the risk could not be adequately mitigated by the proposed risk evaluation and mitigation strategy (REMS).\nThe FDA said that Sanofi said the benefit-risk profile was favorable for patients with nrSPMS because there currently aren't any approved treatments for the subpopulation.\nFDA disagreed and wrote, \"We were unable to identify a population for which the benefit could be clearly established and for which that benefit would be anticipated to outweigh the serious risk of severe DILI to support approval.\"\nFDA's review identified six cases meeting Hy's Law criteria in the tolebrutinib Phase 3 development program out of approximately 2700 subjects, including one subject who died after requiring a liver transplant, which indicates a high level of hepatotoxic risk with tolebrutinib.\nThe letter also noted that in the first 6 months of double-blind treatment of Study EFC16645, 3.6% of tolebrutinib-treated subjects versus 1.9% of placebo-treated subjects experienced aminotransferases greater than 3 times the upper limit of normal.\nAdditionally, the regulator highlighted uncertainties about the analyses provided regarding slowing disability accumulation independent of relapse activities.\n\"Overall, substantial evidence of effectiveness has not been established in a clinically identifiable population for whom the benefits potentially outweigh the risks,\" the FDA said in the letter.\nSNY Price Action: Sanofi shares were up 0.53% at $47.76 during premarket trading on Tuesday, according to Benzinga Pro data.\nRead Next:\nPhoto by HJBC via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601186358","isCrawlerRequest":true}